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http://dx.doi.org/10.1016/j.ccr.2013.05.003SUMMARYDespite success with BRAFV600E inhibitors, therapeutic responses in patients with metastatic melanoma
are short-lived because of the acquisition of drug resistance.We identified amechanismof intrinsicmultidrug
resistance based on the survival of a tumor cell subpopulation. Treatment with various drugs, including
cisplatin and vemurafenib, uniformly leads to enrichment of slow-cycling, long-term tumor-maintaining mel-
anoma cells expressing the H3K4-demethylase JARID1B/KDM5B/PLU-1. Proteome-profiling revealed an
upregulation in enzymes of mitochondrial oxidative-ATP-synthesis (oxidative phosphorylation) in this sub-
population. Inhibition of mitochondrial respiration blocked the emergence of the JARID1Bhigh subpopulation
and sensitized melanoma cells to therapy, independent of their genotype. Our findings support a two-tiered
approach combining anticancer agents that eliminate rapidly proliferating melanoma cells with inhibitors of
the drug-resistant slow-cycling subpopulation.INTRODUCTION
Malignant melanoma is a heterogeneous tumor of neuroectoder-
mal origin that can be cured if excised at an early stage; however,
once disseminated to distant organs, the median survival of
patients drops below 9 months. All major cancer therapiesSignificance
Metastatic melanoma is a heterogeneous tumor of neuroecto
chemotherapies, immunotherapies, and radiotherapies have
aging response rates following BRAFV600E targeting, relapses
anoma cells acquire multiple resistance mechanisms. Howev
tumors, common and intrinsic mechanisms exist that support
cytotoxic agents. We have identified a subpopulation of slow
phenotypic resistance to various therapies, irrespective of the
could increase the efficacy of current treatment regimens andhave failed to persistently increase melanoma patients’ survival
rates. This failure is attributed to different resistance mecha-
nisms, including increased DNA repair and overexpression of
antiapoptotic proteins, such as BCL-2, and drug efflux pumps,
such as ABCB5 (Chen et al., 2009). Despite encouraging
response rates seen with the BRAF inhibitor vemurafenib indermal origin with a median survival less than 9 months. All
failed to persistently increase survival. Despite the encour-
occur after a median duration of 5 months, because mel-
er, even among functionally and genetically heterogeneous
the immediate survival of certain cells against the attack of
-cycling, tumor-maintaining melanoma cells with intrinsic
ir mode of action. Targeting the slow-cycling subpopulation
reduce relapses.
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Inhibition of Slow-Cycling Melanoma CellsBRAFV600E-positive individuals, relapses occur after a median
duration of 5 months following initial tumor shrinkage (Sosman
et al., 2012). Several groups have identified various mechanisms
of acquired therapy resistance in BRAF-targeted melanomas.
Surviving melanomas reactivate pivotal networks, such as the
mitogen-activated protein kinase (MAPK) and phosphoinositide
3-kinase (PI3K) pathways (e.g., through activation of platelet-
derived growth factor receptor b, cRAF-1 kinase, and insulin
growth factor receptor 1 [Nazarian et al., 2010; Villanueva et al.,
2010], dimerization of aberrantly spliced BRAF isoforms [Pouli-
kakos et al., 2011], or by secondary genetic events, such as
genomic amplification of COT, NRAS mutations, or the
MEK1C121S mutation [Johannessen et al., 2010; Wagle et al.,
2011]). However, even among functionally and genetically het-
erogeneous tumors, common and intrinsic survival mechanisms
exist. Cytotoxic agents, including conventional chemotherapy,
targeted therapy, or radiation, most effectively eliminate rapidly
dividing cells (Blagosklonny, 2005). This concept is gainingprom-
inence in the field of cancer research, with several studies
reporting the enrichment of quiescent cancer stem cells after
chemotherapy. For example, slow-cycling glioblastoma cells
survive temozolomide treatment (Chen et al., 2012). Accordingly,
if cell subpopulations can act as major drivers for tumor mainte-
nance andmediate universal therapeutic resistance, approaches
that target this phenotype could increase the efficacy of treat-
ment regimens and reduce the risk of melanoma relapses.
We have recently demonstrated that, even within highly prolif-
erative melanomas, there is a slow-cycling cell subpopulation
that is identifiable by the expression of the histone 3K4 demethy-
lase JARID1B (Roesch et al., 2005, 2010). JARID1B (KDM5B/
PLU-1/RBP2-H1) is a member of the highly conserved family of
jumonji/ARID1 H3K4 demethylases, which are involved in tissue
development, cancer, and stem cell biology (Christensen et al.,
2007; Dey et al., 2008; Yamane et al., 2007). The JARID1Bhigh
slow-cycling subpopulation is required for the continuous tumor
growth of melanoma; however, it does not follow a unidirectional
cancer stem cell hierarchy. The JARID1Bhigh phenotype is
temporarily distinct, dynamic, and can be acquired depending
on the microenvironmental context (Roesch et al., 2010). In this
respect, another study indicates that other types of cancers,
such as breast or lung cancer, also harbor populations of quies-
cent cells that are drug resistant and whose phenotypes can
switch dynamically (Sharma et al., 2010). Interestingly, in the
latter study, slow-cycling cells were characterized by the expres-
sion of the chromatin-remodeling factor JARID1A, a homolog of
JARID1B.
Considering JARID1B’s role in continuous tumor maintenance
(Roesch et al., 2010), we asked (1) whether the subpopulation of
JARID1Bhigh slow-cycling melanoma cells displays lower drug
susceptibility compared to the bulk of tumor cells and (2) whether
this resistant phenotype can be pharmacologically eradicated.
RESULTS
Cytotoxic Treatment of Melanoma Cells Results in the
Enrichment of a Surviving JARID1Bhigh Slow-Cycling
Subpopulation
To assess whether slow-cycling melanoma cells show differ-
ences in the therapeutic response compared to the rapidly prolif-812 Cancer Cell 23, 811–825, June 10, 2013 ª2013 Elsevier Inc.erating bulk, we treated melanoma cultures with various
anticancer drugs. To discriminate between slowly and rapidly
cycling subpopulations, we used a JARID1B- promoter-EGFP-
reporter construct, as previously described (Roesch et al.,
2010). This fluorescence-based model allows both the detection
of slow-cycling melanoma cells based on their expression of
JARID1B and monitoring of the dynamic nature of the JARID1B
phenotype while cells are alive and interacting with their micro-
environment. Prior in vitro and in vivo expression studies
confirmed the correlation between the endogenous expression
of JARID1B and the JARID1B promoter-induced expression of
EGFP (J/EGFP) using an analytical threshold set to themaximum
5% of the fluorescence signal (Figure S1A available online;
Roesch et al., 2010). Cells with an EGFP signal above this
threshold show the highest endogenous JARID1B levels and,
thus, can be reliably selected and analyzed. Two genetically
different melanoma cell lines, WM3734 and 1205Lu, were
stably transduced with this reporter construct and named
WM3734JARID1Bprom-EGFP and 1205Lu JARID1Bprom-EGFP.
When the cell lines were treated with cisplatin at a highly toxic
concentration (20 mM) for 24, 48, and 72 hr, a gradual separation
of the total population emerged into live, 7-aminoactinomycin
(7AAD) and dead, 7AAD+ subpopulations (Figure 1A). With
increasing incubation time, 7AAD cells were incrementally
enriched for J/EGFPhigh cells, whereas 7AAD+ cells were rela-
tively J/EGFPlow. Control cells stably expressing a cytomegalo-
virus (CMV)-promoter-EGFP-reporter construct failed to show
such a separation/enrichment pattern. While the total number
of cells was constantly decreasing with rising cisplatin doses,
the relative number of J/EGFPhigh cells was significantly
increasing in the drug-resistant population (Figures 1B and
S1B). For example, up to 30.2% J/EGFPhigh cells were seen
following 20 mM of cisplatin addition, compared to the 5%
seen in vehicle controls. Immunoblotting confirmed an 3-fold
enrichment for endogenous JARID1B protein after densitometric
normalization to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Figure 1C). Vemurafenib also failed to eradicate all
melanoma cells and enriched for J/EGFPhigh cells, however, to
a lesser extent than seen for cisplatin (Figure 1D). Interestingly,
even when high concentrations of vemurafenib were applied, a
distinct subpopulation of cells remained alive (7AAD) and dis-
played an 3-fold higher fluorescence intensity for J/EGFP
(GMean = 25.55) than the population of vemurafenib-sensitive
(7AAD+) cells (GMean = 8.54; Figure 1D). The surviving mela-
noma cells did not change in their mutational status of BRAF,
as confirmed by DNA sequencing before and after treatment
(data not shown). In a previous publication, we excluded the
acquisition of secondary mutations for a large panel of diverse
melanoma cell lines rendered resistant to BRAF inhibitors. We
have tested 451Lu, Mel1617, WM983B, WM902B, and SKMel28
(parental and resistant pairs; several passages) for mutations in
BRAF, NRAS, TP53, PTEN, KIT,MEK1,MEK2, AKT1, CDKN2A,
and CDK4 (Villanueva et al., 2010).
Interestingly, similar results were observed for other anti-
cancer drugs, such as bortezomib and temozolomide (Fig-
ure 2A). We also note that a number of cells with relatively
low J/EGFP expression can survive various drug treatments,
indicating other potential operating mechanisms of phenotypic
resistance. In contrast to its proposed effect on cancer stem
Figure 1. Cytotoxic Treatment Results in the Relative Enrichment of Therapy-Resistant JARID1Bhigh Melanoma Cells
(A) WM3734 melanoma cells were persistently treated with cisplatin and analyzed for J/EGFP expression by flow cytometry at the indicated time points (left).
Dead cells were detected by 7AAD staining. Control cells were analyzed for C/EGFP expression (right). Depicted is one representative of at least three
independently performed experiments.
(B) MTT cytotoxicity assay of WM3734 cells treated with increasing concentrations of cisplatin (left). Relative percentage of the J/EGFPhigh subpopulation under
escalating cisplatin treatment (right). Both panels show results from 72 hr of treatment.
(C) Immunoblot of JARID1B protein expression in pre- and postcisplatin-treated WM3734 cells at the indicated time points.
(D) Cytotoxicity assay and quantitation of the J/EGFPhigh subpopulation after treatment of WM3734 cells for 72 hr with escalating vemurafenib concentrations
(left and middle). Comparison of the J/EGFP expression levels of 7AAD+ and 7AAD cells (right). Error bars in the cytotoxicity assays represent SD.
See also Figure S1.
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Figure 2. The JARID1Bhigh Subpopulation of Melanoma Cells Is Resistant to a Broad Panel of Anticancer Drugs
(A) Cytotoxicity assays ofWM3734 cells after 72 hr of treatment with the indicated anticancer drugs (left). Flow cytometric determination of the relative percentage
of the J/EGFPhigh subpopulation under these treatments (middle). Typical examples for the corresponding drug-associated distribution of 7AAD and J/EGFP
signals (right).
(B) Frequency of J/EGFPhigh WM3734 cells as measured by flow cytometry after incubation with the indicated compounds over 72 hr. Error bars represent SD.
See also Figure S2.
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Inhibition of Slow-Cycling Melanoma Cellscells (Gupta et al., 2009), the potassium ionophore salinomycin
also showed a strong enrichment of J/EGFPhigh cells. To rule
out an unspecific bias in our model, we tested vitamin D3 as814 Cancer Cell 23, 811–825, June 10, 2013 ª2013 Elsevier Inc.a compound with a different anticancer mechanism (prodiffer-
entiation; Figure 2B). Here, no significant change in J/EGFPhigh
cells was seen. Next, we tested compounds that are expected
Figure 3. The JARID1Bhigh Subpopulation Is
Enriched in Melanomas Resisting Therapy, and
Knockdown of JARID1B Leads to Increased Drug
Sensitivity
(A) NSG mice xenografted with WM3734 melanoma cells
were treated with vemurafenib or vehicle (n = 7). Tumor
weights were assessed after 11 days of treatment (left).
Tumor residues were immunostained for JARID1B expres-
sion (middle), and nuclear-staining signals of each tumor
were scored at 40X magnification in three representative
fields of vision (right, two-sided Wilcoxon two-sample test).
(B) Immunostaining of JARID1B in matched pairs of mela-
noma samples before and relapse under vemurafenib
treatment from three melanoma patients.
(C) Two different JARID1B knockdown clones
(sh_JARID1B_58 and 62) of WM35 melanoma cells and
the sh_scrambled control were starved for 4 days at 0%
FCS and subsequently stimulated by 10% FCS for 8 hr. The
bar graph shows one example of five independent experi-
ments of propidium iodide-based cell cycle analysis (left).
The immunoblot shows pRB phosphorylation (right).
(D) NSG mice were xenotransplanted with WM3734
melanoma cells stably knocked down for JARID1B
(sh_JARID1B) or with control cells (sh_scrambled). Each
mouse received 104 cells (n = 8). After tumors reached an
average volume of 200 mm3, mice were treated with
bortezomib (left, BOR), vemurafenib (right, VEM), or vehicle
(PBS). Tumor volumes were measured at the indicated time
points. Error bars represent SD.
See also Figure S3.
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Inhibition of Slow-Cycling Melanoma Cellsto diminish the slow-cycling phenotype, such as the histone
deacetylase inhibitor trichostatin A (Sharma et al., 2010) or
the Sp1 inhibitor mithramycin A (Sp1-binding sites within the
JARID1B promoter are indicative of a possible regulatory
potential); however, both compounds failed to reduce the
J/EGFPhigh subpopulation (Figure 2B). Similarly, leflunomide,
which was suggested to interfere with developmental pro-
cesses in melanocytes and melanoma growth (White et al.,Cancer Cell 22011), did not reduce the J/EGFPhigh subpopu-
lation in our model (Figure S2).
The in vivo relevance of our observations was
confirmed in WM3734 cells xenografted to
NOD/LtSscidIL2Rgnull (NSG) mice and treated
with vemurafenib (Figure 3A). While tumors
decreased in size due to treatment, the number
and staining intensity of resistant JARID1Bhigh
cells significantly increased. Importantly, a clear
increase in JARID1B-expressing cells could be
observed in three out of four matched pairs of
patients’ melanomas that relapsed under vemur-
afenib (Figure 3B). Together, these data indicate
a universal resistance of the slow-cycling
JARID1Bhigh melanoma subpopulation against
various anticancer agents.
Knockdown of JARID1B Leads
to Increased In Vivo Sensitivity
to Antimelanoma Treatment
Previous studies suggested that the abrogation
of the slow-cycling phenotype by JARID1B-specific knockdown leads in vitro and in vivo to increased cell
proliferation followed by melanoma exhaustion (Roesch et al.,
2010). To quantify the shifts in cell-cycle progression, depending
on the presence or absence of JARID1B, we performed cell-
cycle experiments in WM35 melanoma cells stably knocked
down for JARID1B (Figures 3C and S3). WM35 was chosen
because changes in cell cycle of this low tumorigenic cell line
could be better assessed compared to lines with high doubling3, 811–825, June 10, 2013 ª2013 Elsevier Inc. 815
Cancer Cell
Inhibition of Slow-Cycling Melanoma Cellsrate. Influences of cell densities and growth factors were consid-
ered. Cells were seeded at different densities and serum-starved
at 0% fetal calf serum (FCS) for 4 days to synchronize the cell
cycles. Under these conditions, knockdown of JARID1B led to
an increase in S phase cells when compared to the control.
Following stimulation with 2%, 5%, and 10% FCS over 4, 8,
16, and 24 hr, JARID1B knockdown cells shifted to G2/M. The
most consistent changes in the cell cycle were seen after 8 hr
of 10% FCS stimulation. Across five independently performed
experiments, we saw an average decrease in G1 phase cells in
JARID1B knocked down cells by 20% (ranging from 5% to
40%; the latter experiment is depicted in Figure 3C), while
S phase cells increased by 6% (2%–12%), and G2/M phase
cells by 14% (1%–31%). As predicted by previous studies
showing JARID1B/retinoblastoma protein (pRB)-dependent
cell cycle control (Roesch et al., 2006), JARID1B knockdown
was accompanied by an increase in pRB phosphorylation at
the JARID1B-specific phosphorylation site Ser795 (Figure 3C).
Consequently, we asked if the inhibition of JARID1B could affect
the therapeutic responsiveness of melanoma cells to anticancer
drugs while releasing them from their slow-cycling phenotype.
Indeed, stable knockdown of JARID1B in WM3734 melanoma
cells xenografted to NSG mice led to increased cell proliferation
accompanied by a significant sensitization to different treat-
ments (Figure 3D). JARID1B knockdown plus bortezomib
showed an additive effect, improving the moderate antimela-
noma effect of bortezomib to an almost complete stasis of tumor
growth. When we combined JARID1B knockdown with vemura-
fenib, which by itself dramatically prevents melanoma growth,
we still observed a decrease in the average tumor volume below
that of the treatment-starting volume. Because of the biological
variability of tumor sizes, this effect was not significant in the
multivariance analysis of variance (MANOVA), but an analysis
of the change in the logarithm of volume per unit time by t test
had significantly different rates. In sum, these results support
the hypothesis that targeting the slow-cycling cell phenotype
can sensitize melanoma to anticancer approaches, including
chemotherapeutics and molecular-targeted drugs.
Dynamics of the Therapy-Resistant JARID1Bhigh
Phenotype
According to our previous observations, the progeny of both
J/EGFPhigh and J/EGFPlow cells can dynamically interconvert
into the opposing phenotype, indicating a flexible system that
is dependent on the microenvironmental context (Roesch
et al., 2010). Thus, we asked (1) if the newly developing proge-
nies of initially sorted J/EGFPhigh or J/EGFPlow cells show a dif-
ferential drug response and (2) if the observed enrichment of
J/EGFPhigh cells after anticancer treatment results from selection
of J/EGFPhigh cells or induction of J/EGFPhigh expression. In reg-
ular culture, spontaneous phenotype interconversion usually
becomes visible within a few days after fluorescence-activated
cell sorting (FACS) of the two populations. For example, 69.9%
of FACS-sorted J/EGFPhigh cells turned negative 72 hr after sep-
aration (Figure 4Ac, upper left plus lower left quadrant), while in
total, 3.5% of the progeny of sorted J/EGFPlow cells became
J/EGFPhigh (Figure 4Ae). When sorted cells were treated with
20 mM cisplatin for 72 hr, we saw no substantial enrichment for
J/EGFPhigh cells in the progeny of initially J/EGFPhigh cells, indi-816 Cancer Cell 23, 811–825, June 10, 2013 ª2013 Elsevier Inc.cating that no additional JARID1B-expression cells were
induced (summarized upper and lower right quadrants; Fig-
ure 4Ac versus Figure 4Ad). Interestingly, most newly developed
J/EGFPlow cells became 7AAD+ under cisplatin treatment (Fig-
ure 4Ac versus Figure 4Ad, upper and lower left quadrants).
The apparent preference for JARID1B induction in the progeny
of J/EGFPlow cells (Figure 4Ae versus Figure 4Af) was counter-
acted by an increased rate of cisplatin-induced cell death in cells
derived from the J/EGFPlow population. Manual counts revealed
a significantly lower number of surviving cells in the progeny of
sorted J/EGFPlow cells compared to the progeny of J/EGFPhigh
cells (p < 0.05 for 5 mM and 10 mM cisplatin; data not shown).
Together with the results from consecutive measurements of
JARID1B messenger RNA (mRNA) under cisplatin treatment
that did not show transcriptional upregulation (Figure 4A), we
concluded that the major mechanism for the enrichment of
J/EGFPhigh cells following therapy is a selection of pre-existent
JARID1Bhigh slow-cycling cells. However, to a lesser extent,
JARID1B induction may also occur (e.g., shifting cells with inter-
mediate JARID1B expression to higher levels).
When cells were long-term challenged with cisplatin, the
J/EGFPhigh subpopulation remained constantly elevated over
several weeks in a dose-dependent manner. The cisplatin-
induced elevation of J/EGFPhigh cells was fully reversible
following drug withdrawal (Figure 4B). In line with the concept
of dynamic phenotype switching (Roesch et al., 2010), drug-
resistant cells that are enriched for JARID1B can regain the
original cell distribution and J/EGFP ratios after drug removal.
Moreover, cisplatin-surviving JARID1B-enriched cells gave rise
to fewer but significantly larger (i.e., rapidly growing) three-
dimensional (3D) colonies in soft agar compared to untreated
cells (Figure 4C). This observation is reminiscent of earlier clono-
genicity and single-cell dilution assays showing that untreated
FACS-isolated J/EGFPhigh cells give rise to a rapidly proliferating
progeny with elevated repopulation capacity when compared to
JARID1Blow cells (Roesch et al., 2010).
Bioenergetic Metabolism Plays an Important Role
in the Survival of Slow-Cycling Melanoma Cells
We next designed experiments to unravel druggable targets that
are specifically activated in slow-cycling melanoma cells. Since
global gene expression screening with complementary DNA
microarrays did not provide significant hit candidates in FACS-
sorted J/EGFPhigh versus J/EGFPlow or JARID1B knockdown
versus control cells (data not shown), we performed quantitative
proteome profiling. Following our established protocols for isola-
tion of slow-cycling melanoma cells (Roesch et al., 2010), we
costained WM3734JARID1Bprom-EGFP cells with the PKH26 dye
and then FACS-isolated the label-retaining and J/EGFPhigh sub-
population versus nonlabel-retaining J/EGFPlow cells after a
period of 4 weeks of cell divisions. Prior to sorting, the cells
were grown as melanospheres to attain a more stringent
J/EGFP phenotype, as previously reported (Roesch et al.,
2010). Tryptic digests of the cell lysates were analyzed by liquid
chromatography-mass spectrometry/mass spectrometry.
Label-free computational quantitation identified 423 proteins
with significant expression changes between label-retaining
J/EGFPhigh cells and nonlabel-retaining J/EGFPlow cells with a
p value < 0.001. Unexpectedly, neither common cancer target
Figure 4. Dynamics of the Therapy-Resistant JARID1Bhigh Phenotype
(A) WM3734JARID1Bprom-EGFP cells were FACS-sorted according to their J/EGFP expression, and the isolated subfractions were cultured as adherent monolayers
overnight. After subsequent treatment for 72 hr, the frequencies of J/EGFPhigh and J/EGFPlow cells were again quantified by flow cytometry. Dead cells were
detected by 7AAD staining. JARID1B mRNA expression was quantified by quantitative PCR.
(B) Flow cytometric detection of J/EGFPhigh WM3734 cells after prolonged incubation with different concentrations of cisplatin and after drug recovery.
(C)Colony-forming assay ofWM3734 cells that underwent cytotoxic pulse treatment prior to seeding. Cellswere treated for 72 hrwith cisplatin or vehicle. Surviving
cells were subsequently embedded into soft agar (2,000 cells/well). Colony sizes and numbers were digitally quantified and color-coded, with dark blue colonies
representing large colonies above 1,000 pixels. Shown are results from two independent experiments, each performed in triplicate. Error bars represent SD.
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Inhibition of Slow-Cycling Melanoma Cellsnor drug resistance-related protein could be detected by this
approach. Instead, we found a differential regulation of a number
of mitochondrial proteins with particular functions in bioener-getic metabolism (Table S1). Many of the upregulated proteins
play a major role in cell respiratory electron transport (oxidative
phosphorylation [OXPHOS]), such as nicotinamide adenineCancer Cell 23, 811–825, June 10, 2013 ª2013 Elsevier Inc. 817
Figure 5. Elevated Mitochondrial Bioenergy
Metabolism in the JARID1Bhigh Subpopu-
lation
(A) Immunoblotting of mitochondrial respi-
ratory enzymes in FACS-sorted J/EGFPhigh and
J/EGFPlow WM3734 cells. Fold changes were
normalized to GAPDH.
(B) Relative mitochondrial ATP levels in control
(CTRL) or JARID1B-transfected WM3734 cells
were measured using the ATP sensor protein
ATEAM. Representative ATEAM ratio images (top) and
summarized ATEAM ratio values in control (n = 72)
and JARID1B-transfected (n = 47) cells (bottom).
(C) Mean oxygen consumption of control- (black) or
JARID1B-transfected (red) WM3734 cells pre-
sented as decline of trityl radical intensity per
minute per 106 cells (left). Mean oxygen concen-
tration in presence of control or JARID1B-trans-
fected WM3734 cells presented as trityl intensity
per 106 cells. Each data point is an average of
seven independent experiments.
(D) Relative H2O2 levels were measured in
JARID1B-transfected WM3734 cells using the
H2O2 sensor protein Hyper. Columns represent
averaged Hyper ratio values of control- (black,
n = 71) or JARID1B-transfected cells (red, n = 48).
To test the role of mitochondria as source of H2O2,
cells were treated with 1 mM oligomycin (dark gray)
or 1 mM rotenone (light gray). Numbers of cells
averaged were: CTRL plus oligomycin (n = 50),
CTRL plus rotenone (n = 42), JARID1B plus oligo-
mycin (n = 45), and JARID1B plus rotenone (n = 52).
In a confirmation experiment with WM3734 cells
transfected with pCAGGS-JARID1B-IRES-RFP
(right), positively transfected cells were selected for
analysis based on the expression of red fluorescent
protein (RFP). Error bars represent SEM.
See also Table S1.
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Inhibition of Slow-Cycling Melanoma Cellsdinucleotide (NADH) dehydrogenase (complex I of themitochon-
drial electron transport chain), ubiquinol cytochrome c reductase
(complex III), cytochrome c oxidase (complex IV), and ATP
synthase. In contrast, glycolytic hexokinase I and II were down-
regulated. Immunoblotting of lysates from J/EGFP-sorted cells
confirmed upregulation of ATP synthase, NADHdehydrogenase,
ubiquinol-cyctochrome C reductase-binding protein, and
cytochrome c oxidase in J/EGFPhigh cells (Figure 5A). WM3734
cells transiently overexpressing JARID1B had a higher mito-
chondrial energy production compared to the mock control (Fig-
ure 5B). Accordingly, JARID1B-overexpressing WM3734 cells
consumed 50% more oxygen than control cells (Figure 5C).
Treatment with different concentrations of oligomycin and rote-
none severely reduced the oxygen consumption by up to 94%,
indicating a major role for mitochondria in this process (data
not shown). Because highmitochondrial electron transfer activity
can lead to increase in superoxide and hydrogen peroxide (H2O2)
production, we analyzed the H2O2 level. JARID1B-overexpress-
ing cells generated 76% more H2O2 than control cells 60–72 hr
after transfection (Figure 5D). The H2O2 increase was completely
abolished by treatment with oligomycin or rotenone. These
results suggest that redox signaling may play an important role818 Cancer Cell 23, 811–825, June 10, 2013 ª2013 Elsevier Inc.for JARID1Bhigh cells. Furthermore, high oxygen consumption
can ultimately lead to hypoxic conditions, which is known to
favor the JARID1Bhigh slow-cycling phenotype (Xia et al., 2009;
Roesch et al., 2010).
Targeting the Mitochondrial Respiratory Chain Inhibits
the JARID1Bhigh Subpopulation and Reveals Long-Term
Effects against Melanoma Cells
Inhibition of the mitochondrial respiratory chain has been
reported to exert tumor-suppressive effects in different types
of cancers, including neuroectodermal glioblastoma cells (Hao
et al., 2010). Since enzymes of almost all respiratory chain
complexes were found differentially regulated in slow-cycling
J/EGFPhigh cells (Table S1), we explored representative inhibi-
tory tool compounds, such as (1) the ATP-synthase inhibitors
oligomycin and Bz-423, (2) the NADH dehydrogenase
(complex I) inhibitors rotenone and phenformin, and (3)
antimycin A, which inhibits the ubiquinol cytochrome c reduc-
tase in a series of preliminary cytotoxicity assays (data not
shown). Here, ATP-synthase and complex I inhibitors revealed
the most prominent results; thus, these were selected for subse-
quent studies. High concentrations of oligomycin were reported
Cancer Cell
Inhibition of Slow-Cycling Melanoma Cellsto exert unspecific effects in eukaryotes, due to the uncoupling
of the respiratory chain (Charton et al., 2004). Therefore, MTT
assayswere used to estimate theminimal concentration of oligo-
mycin that could cause mitochondrial uncoupling in our cell
lines, since reduction of the tetrazolium compound MTT is
dependent on intact mitochondrial electron transport (Grazette
et al., 2004). We observed an abrupt decrease in MTT reduction
above an oligomycin concentration of 2.5–5 mg/ml, independent
of the incubation time and the genetic background of all cell lines
tested (Figure 6A; depicted are WM3734 as an example). These
results are in line with oligomycin concentrations that were
reported by others to specifically block oxidative phosphoryla-
tion (Hao et al., 2010). Thus, we considered oligomycin concen-
trations less than 2.5 mg/ml to work through the specific inhibition
of the ATP-synthase and not through mitochondrial uncoupling.
We next asserted that low-dose oligomycin still leads to func-
tional and significantly measurable effects, such as a decrease in
ATP production or increase in lactate secretion in WM3734 cells
(Figure 6B), and subsequently confirmed this for a panel of
genetically different melanoma lines under normoxic and hypox-
ic conditions (Figure 6C). The detected changes in ATP and
lactate were comparable to those measured by others for a
number of different cell types (Hao et al., 2010). Interestingly,
ATP-synthase inhibition was accompanied by a complete loss
of endogenously expressed JARID1B protein after 72 hr of
oligomycin treatment (Figure 6D). Also, the enrichment of
JARID1Bhigh cells usually seen after hypoxic treatment was
inhibited by low-dose oligomycin.
Due to the evolutionary link between nonproliferative and
OXPHOS-dependent cell phenotypes (Berridge et al., 2010;
Jose et al., 2011; Vander Heiden et al., 2009), we next asked if
inhibition of mitochondrial ATP production also influences the
cell cycle of melanoma cells. In fact, even very low doses of
oligomycin (0.01 mg/ml) caused a measurable decrease in the
percentage of cells in G1/0 phase and an increase in the percent-
age of cells in S- and G2/M-phase compared to vehicle controls.
To optimize the readout, cells were serum-starved for 4 days and
subsequently stimulated with FCS for 8 and 16 hr (Figure 6E).
After 24 hr, cell cycle phases were again equal in oligomycin
and vehicle control-treated cell groups (data not shown). Despite
the increase in proliferative cell cycle phases, we found a relative
decrease in overall cell numbers after oligomycin treatment
compared to controls (Figure 6F). A likely explanation for this
paradox is that simultaneously to (or after) the acceleration of
the cell cycle, a considerable portion of the cells is undergoing
cell death, as indicated by independently performed 7AAD stain-
ing and subsequent flow cytometric analysis (e.g., 20% dead
cells after 72 hr of 0.1 mg/ml oligomycin; Figure S4A). Short-
term analysis of oligomycin’s effect on total cell numbers
showed that the cell population slightly expands at low doses
(Figure 6F, left panel), whereas high doses starting from
5 mg/ml caused persisting or decreasing cell numbers, possibly
due to highly toxic mitochondrial uncoupling. The full effect of
the antitumor potential of low-dose oligomycin became visible
in long-term colony formation assays. Here, a significant reduc-
tion in colony growth was seen after 3 weeks of treatment (Fig-
ure 6F, right panel), which is reminiscent of the results previously
reported for JARID1B knockdown (Roesch et al., 2010). Short-
term treatment of WM3734 cells with the ATP-synthase inhibitorBz-423 and the complex I inhibitors rotenone and phenformin
confirmed these findings (Figures S4B–S4D). In conclusion,
this suggests that pharmacological targeting of the mitochon-
drial respiratory chain can inhibit the JARID1Bhigh slow-cycling
subpopulation and reveal long-term suppressive effects in mel-
anoma cells.
Inhibition of the Mitochondrial Respiratory Chain
Overcomes Intrinsic Multidrug Resistance of Melanoma
We asked if inhibition of the mitochondrial respiration could
counteract the intrinsic multidrug resistance mediated by slow-
cycling melanoma cells. Flow cytometric quantitation of
J/EGFP levels in WM3734 cells (Figure 7A) and 1205LU cells
(Figure S5A) revealed a significant blockade of the JARID1Bhigh
subpopulation when cells were treated with the combination of
cisplatin plus oligomycin. Similar results were seen for Bz-423,
which also acts as an ATP-synthase inhibitor (Figure S5B).
Even treatment with extremely low doses of oligomycin
(0.001 mg/ml; Figure S5C) still blocked the enrichment of
J/EGFPhigh cells. At 0.001 mg/ml, single-agent oligomycin did
not induce substantial cell death, as measured by 7AAD flow
cytometry in WM3734 cells (Figure S4A); however, when com-
bined with cisplatin, the overall number of dead cells strongly
increased (Figure S5C). Immunoblots revealed a complete loss
of endogenous JARID1B under oligomycin cotreatment, over-
coming the cisplatin-induced enrichment of JARID1B protein
after 24, 48, and 72 hr (Figure 7A). Cytotoxicity assays confirmed
that the combination with oligomycin sensitizes melanoma cells
to cisplatin treatment, but depending on the cell line used, the
contribution of single-agent oligomycin to cell killing can vary
(Figure 7B). MeWo cells, the melanoma cell line with the lowest
oligomycin response in lactate secretion (Figure 6C), were not
sensitized to cisplatin, indicating that the combination with oligo-
mycin is not universally cytotoxic, but instead, responses match
our mitochondrial activity-based hypothesis. The tumor sup-
pressive potential of combinatorial ATP-synthase inhibition
was further demonstrated in 3D collagen-embedded spheroids
of 1205Lu cells, a model which more readily mimics the mela-
noma microenvironment. The combination of oligomycin plus
vemurafenib more potently inhibited cell invasion into collagen
than each drug alone (Figure 7C; p < 0.0003). Notably, treatment
of WM3734 cells with a single pulse of low-dose oligomycin plus
cisplatin over 72 hr substantially reduced long-term growth in
soft agar and the number of 3D colonies remained at almost
undetectable levels, even after 5 weeks of culture in drug-free
medium (Figure 7D). This effect reached statistical significance
with p < 0.02 when large colonies above a diameter of 10 mm
were counted. Consistent with the observation that significantly
larger colonies grew from cisplatin pretreated cells (that were
enriched for the J/EGFPhigh subpopulation; Figure 4C), these
results indicate that (1) adding mitochondrial inhibitors to com-
mon anticancer treatment significantly diminishes the number
of cells with high repopulation and invasion potential and (2)
that even a relatively short-term treatment can yield a sustained
antitumor effect.
Mitochondrial inhibition as a combinatorial strategy against
cancer drug-induced enrichment of slow-cycling JARID1Bhigh
melanoma cells was further confirmed for the complex I inhibi-
tors rotenone and phenformin. Phenformin is used in the clinicsCancer Cell 23, 811–825, June 10, 2013 ª2013 Elsevier Inc. 819
Figure 6. Inhibition of the Mitochondrial ATP Synthase Inhibits the JARID1Bhigh Subpopulation and Reveals Long-Term Melanoma
Cell-Suppressive Effects
(A) MTT reduction curve of regularly cultured WM3734 melanoma cells after oligomycin treatment.
(B) Total cellular ATP levels were luminometrically determined in WM3734 cells after 24 hr of treatment with oligomycin at the indicated concentrations (left).
Lactate production was measured in WM3734 cell culture supernatants after 24 hr of oligomycin. Ethanol (EtOH, diluted 1:1000) was used as vehicle control.
Shown are means of three independently performed experiments.
(C) Lactate measurement in a panel of genetically diverse melanoma cell lines under normoxic versus hypoxic culture conditions after 24 hr of treatment.
(D) Immunoblot of JARID1B protein expression in WM3734 cells treated with oligomycin for 72 hr at the indicated concentrations (top). Frequency of J/EGFPhigh
WM3734 cells under 72 hr of hypoxia versus hypoxia plus oligomycin (oligo) treatment as determined by flow cytometry (middle). Immunoblots of endogenous
JARID1B expression in MelJuSo and SKMel5 melanoma cells under hypoxia and hypoxia plus oligomycin treatment (bottom).
(legend continued on next page)
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Figure 7. The Combination of Anticancer Agents plus Inhibition of the Mitochondrial ATP-Synthase Overcomes the Enrichment of the
JARID1Bhigh Subpopulation In Vitro
(A) Relative percentage of the J/EGFPhigh subpopulation under combinatorial treatment of WM3734 cells for 72 hr with cisplatin (cis) and oligomycin as deter-
mined by flow cytometry (left). Ethanol (EtOH) was used as vehicle control. Immunoblots of the endogenous JARID1B protein expression of WM3734 cells under
cotreatment with oligomycin at the indicated time points (right).
(B) Cytotoxicity assays of melanoma cell lines after 72 hr of cotreatment with cisplatin (cis) and oligomycin (oligo).
(C) Three-dimensional growth/invasion/survival assay of 1205Lu cells treated with vemurafenib (vem) and oligomycin (oligo) for 96 hr. Colony sizes were
quantified digitally based on the relative number of pixels. Scale bar represents 500 mm.
(D) Soft agar colony-forming assay of WM3734 cells after 72 hr pulse treatment with oligomycin (left) and oligomycin plus cisplatin (right). Colonies were counted
manually after 5 weeks of growth. Results shown are from one of two independent experiments. Error bars represent SD.
See also Figure S5.
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emergence of JARID1Bhigh cells during antimelanoma treatment
(Figures 8A and S6A–S6D). Immunoblots and immunohisto-
chemistry of phenformin-treated cells confirmed that complex I
inhibition affects the endogenous JARID1B phenotype in vitro
and in vivo (Figures S6C and S6D). Similar to the combinations
of bortezomib or vemurafenib with JARID1B gene knockdown
shown in Figure 3D, the mitochondrial inhibition by phenformin
improved the tumor-suppressive potential of vemurafenib in
xenotransplanted melanomas in vivo (Figures 8B and S6D). Sta-(E) WM3734 cells were starved at 0%FCS and then released by 10% FCS for 8 an
propidium iodide-based cell cycle analysis. Dead cells (SubG1) were gated out.
(F) Short-term effects of increasing concentrations of oligomycin on total WM373
reduction as measured by 3D soft agar colony formation assays (bidaily treatme
See also Figure S4.tistical overall significance was shown by MANOVA (p = 0.0263).
Significant differences between the combination and single
treatments were seen after adjusting for multiple hypothesis
testing (combination versus vemurafenib was p = 0.022, versus
phenformin p = 0.010, and versus control p = 0.010). Altogether,
these findings suggest that multiresistant, slow-cycling mela-
noma cells are susceptible to the inhibition of the mitochondrial
respiratory chain and that the oxidative energymetabolism could
be a prime target to overcome intrinsic drug resistance in
melanoma.d 16 hr. The bar graph shows one example of three independent experiments of
4 cell numbers as determined by crystal violet assays (left). Long-term growth
nt, right). Error bars represent SD.
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Figure 8. The Effect of Anticancer Agents Is Increased In Vitro and In Vivo by the Combination with Complex I Inhibitors
(A) Flow cytometric pattern of 7AAD and J/EGFP signals in cultured WM3734 cells after 72 hr of treatment with cisplatin and rotenone.
(B) SCID beige mice were xenotransplanted with 105 SKMel28 human melanoma cells (left, n = 7 per treatment group, n = 6 in vehicle group), NSG mice with
53 104WM3734 cells (right, n = 8 per group). SKMel28 tumors were treated when an average volume of120mm3 was reached, WM3734 tumors at an average
volume of 200 mm3. Tumor volumes were assessed every other day. Groups marked with # were terminated earlier due to excessive tumor growth. Error bars
represent SEM.
See also Figure S6.
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Despite recent discoveries in the area of therapy resistance in
melanoma, we do not fully know how therapeutic escape arises
and if it is the result of an evolutionary process under treatment,
from the selection of pre-existing resistant subpopulations, or a
combination of both. Likely, even among functionally and genet-
ically heterogeneous tumors, common mechanisms may exist
that allow cells to survive in harsh conditions in general. Based
on our experience with vemurafenib-resistant clones in vitro,
we observed that functionally acquired resistance in cell lines
that are initially vemurafenib-sensitive takes time to develop
but eventually leads to reactivation of the MAPK and PI3K path-
ways (Villanueva et al., 2010). Intrinsic resistance conferred by
the slow-cycling cell phenotype could represent an additional
and universal protection mechanism that helps cells survive
the very first contact with various cytotoxic agents and provides
cells with added survival time to establish longer-lasting second-
ary resistance mechanisms. A major challenge for successful
therapy is that these slow-cycling cells can be present at any
stage of the disease and that this phenotype can be dynamically
acquired by other melanoma cells, depending on the microenvi-
ronmental context, thus representing a ‘‘moving target’’ (Roesch
et al., 2005, 2010).
Our findings indicate that the slow-cycling phenotype reflects
a metabolic state that is characterized by high expression of
mitochondrial bioenergetic enzymes relative to the rapidly prolif-
erating tumor bulk population. Otto Warburg predicted that
cancer cells generally rely on an increase in glucose uptake,822 Cancer Cell 23, 811–825, June 10, 2013 ª2013 Elsevier Inc.the enhancement of glycolysis and lactate production, along
with the absence of oxidative respiration, despite the presence
of sufficient oxygen concentrations (Warburg et al., 1924). He
erroneously suggested defective mitochondria as a possible
cause. However, it is becoming clear now that mitochondria in
cancer cells are mostly intact and may play an important role
in tumor growth (Caro et al., 2012; Weinberg et al., 2010). The
cells’ decision to employ glycolysis or oxidative phosphorylation
for their energy supply depends onmultiple factors, including the
cancer type and stage, the sequence of oncogenes activated,
which can directly influence mitochondrial metabolism, the cur-
rent microenvironmental context, and also the rate of cell prolif-
eration (Berridge et al., 2010; Jose et al., 2011; Vander Heiden
et al., 2009). Our results support the general hypothesis that
slow-cycling cells rely more on oxidative phosphorylation,
whereas rapidly growing cells are characterized by high glycol-
ysis (Berridge et al., 2010; Jose et al., 2011; Vander Heiden
et al., 2009). As previously shown by others, the blockage of
glycolysis by bromopyruvate treatment is only efficient on rapidly
growing cells and barely useful to decrease the growth rate of
tumor cells with slow proliferation (Jose et al., 2011). This obser-
vation together with ours indicates that cell cycling and energy
metabolism represent interwoven biologic processes that holis-
tically contribute to the phenotype of tumor cell subpopulations.
With regard to intrinsic drug susceptibility, we found that the
JARID1Bhigh slow-cycling phenotype is not responding to exog-
enous cell cycle influences, such as serum starvation (data not
shown). Since depletion of JARID1B does affect cell cycle
phases, we would consider JARID1B expression to be a ‘‘driver’’
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ment with the multi-cyclin-dependent kinase (CDK) inhibitor
dinaciclib resulted in massive cell death rather than in prolifera-
tion arrest and thus passively selected for JARID1Bhigh cells,
as seen before for other anticancer agents (data not shown).
We further suggest that consideration of single biologic features,
such as cell cycling, without the metabolic contribution may not
be sufficient to predict therapeutic response. For example,
MeWo cells, which are known to have a high ability to metabolize
glutamine in the (reversed) tricarboxylic acid (TCA) cycle as an
alternative energy source (Scott et al., 2011), responded least
to cytotoxic killing and mitochondrial inhibition, although having
a rather high proliferation rate (and low endogenous JARID1B
expression; data not shown).
We cannot exclude the possibility that our initial proteome
profiling strategy may have missed additional important factors
contributing to the biology of slow-cycling cells. Therefore, we
analyzed common molecular players of melanoma tumorigen-
esis by immunoblotting of sorted J/EGFPhigh versus J/EGFPlow
cells. We found no difference in MAPK activation (measured by
pMEK and pERK levels) nor in the expression of the apoptosis
markers BCL-2, MCL-1, and BIM or the cell-cycle regulators
CDK2, CDK4, and CDK9 (data not shown). Interestingly, we
found an increase in pAKT in J/EGFPhigh cells that correlates
well with our previous finding that reactivation of PI3K signaling
can overcome vemurafenib’s cytotoxicity in melanoma cells (Vil-
lanueva et al., 2010). The relevance of this finding with regard to
therapeutic strategies comprising combinatorial inhibition of
PI3K in slow-cycling cells will be the subject of future studies.
Considering the heterogeneity of melanoma, we are currently
delineating additional molecular mechanisms underlying resis-
tance of the JARID1Bhigh slow-cycling phenotype. However,
non-JARID1B-related phenotypic resistance is likely to occur,
and all potential resistance mechanisms could contribute to
melanoma recurrence.
Our data confirm that slow-cycling melanoma cells of different
genetic backgrounds are intrinsically resistant to various anti-
cancer drugs and are characterized by the presence of several
key enzymes of oxidative energy metabolism. Depletion of the
JARID1Bhigh slow-cycling phenotype either by gene knockdown
or by targeting of its bioenergetic metabolism sensitizes mela-
noma for amore pronounced and long-lasting therapeutic effect.
Selective targeting of the slow-cycling subpopulation in combi-
nation with conventional tumor ‘‘debulking’’ strategies could
help to eliminate a dramatically higher percentage of melanoma
cells and significantly prolong the therapeutic response in
patients with malignant melanoma.EXPERIMENTAL PROCEDURES
Melanoma Cell Lines, Tissue, and Vector Constructs
Establishment and studying of noncommercial melanoma cell lines from
human tumor samples was approved by the Internal Review Boards of the
University of Pennsylvania School of Medicine and TheWistar Institute. Immu-
nohistochemical staining of human melanoma samples was approved by the
ethics committees of the University of Frankfurt and the Saarland University.
Informed consents were obtained from all participating subjects. For details
on cell culture techniques, see Supplemental Experimental Procedures. The
consistency of cellular genotypes was confirmed by DNA fingerprinting at the
Department of Human Genetics of The Saarland University Hospital. The lenti-viral vector constructs for stable knockdown of JARID1Bwere purchased from
Sigma. Details on lentiviral pLU-JARID1Bprom-EGFP-Blast, pLU-CMVprom-
EGFP-Blast, and transient transfection with pBIND-RBP2H1(JARID1B) were
previously described (Roesch et al., 2008, 2010).
Detection of JARID1B and Flow Cytometry of J/EGFP Signals
For immunoblotting and immunostaining, rabbit polyclonal anti-JARID1B anti-
bodies (Novus NB100-97821 and 22260002) were used, following established
protocols (Roesch et al., 2010). Quantitative real time RT-PCR was performed
on a StepOnePlus instrument (Applied Biosystems) using self-designed
primers or primers from the Harvard primer bank as described earlier (Roesch
et al., 2010). Flow cytometric detection of JARID1B promoter-driven EGFP sig-
nals was performed using a FACSCanto II (BDBiosciences) as described in the
supplements. Dead cells were excluded by staining for 7AAD. Fluorescence-
activated cell sorting was done on a Cytomation MoFlo (DakoCytomation) or a
FACSAriaIII (BD Biosciences) instrument.
Cell Proliferation and Three-Dimensional Growth/Invasion/Survival
Assays
Cell proliferation was quantified by MTT and crystal violet assays according to
standard protocols. Anchorage-independent colony formation was measured
in 0.35% soft agar assays and quantified manually or digitally as described
before using Image Pro Plus 7.0 (Roesch et al., 2010). Collagen-embedded,
three-dimensional melanoma spheroids were prepared and treated with inhib-
itors at the designated concentrations for 72 hr, as previously described
(Smalley et al., 2006). Following treatment, spheroids were imaged using a
Nikon-300 inverted fluorescence microscope. To quantitate invasion into the
matrix, borders were established around the invasive edge based on an
ImageJ-defined cell density parameter, and the same parameters were
applied to all images.
Measurement of ATP and Lactate
Total cellular ATP was measured using the ATP-based CellTiter-Glo kit (Prom-
ega) according to the manufacturer’s instructions. Each well on a 96 well plate
was seeded with 2,000 cells, which were incubated with compounds at desig-
nated concentrations over varying time points (1, 2, 4, and 24 hr). Lumines-
cence was measured on a Tecan M200 Infinite plate reader. Mitochondrial
ATP levels were determined using the mitochondrial ATP sensor protein ATEAM
as reported (Imamura et al., 2009) and described in the Supplemental Informa-
tion. For lactate measurement, 105 cells were plated per well on a six well plate
and treated with compounds over 6, 24, or 72 hr. Cell culture supernatant
(500 ml) was collected and centrifuged to remove any cellular debris. Subse-
quently, an aliquot of 100 ml was analyzed using Roche’s automated Modular
Analytics system.
In Vivo Melanoma Models
All animal experiments were performed in accordance with institutional and
national guidelines and regulations. The protocols have been approved by
the Wistar IACUC or the Saarland Veterinary Administration. NSG and severe
combined immunodeficiency (SCID) beige mice were used for xenotransplan-
tation. WM3734 or SKMel28 human melanoma cells were subcutaneously
injected at a Matrigel/culture medium ratio of 1:1. Mice were treated with (1)
bortezomib every other day (20 mg per intraperitoneal injection), (2) with
vemurafenib every 12 hr (100 mg/kg per oral gavage), or (3) for combination
studies with vemurafenib (15 mg/kg) plus phenformin (150 mg/kg; Appleyard
et al., 2012) every 12 hr. Buffered saline or 0.1% Tween 80/0.5% methylcellu-
lose served as vehicle controls. Treatment started at an average tumor volume
of 120–200 mm3. Tumor growth was measured every 2 or 3 days
using a caliper. Tumor volumes were calculated according to the formula
V = WxDxH [mm3].
Statistics
MANOVA was used to evaluate differences between treatment groups; the
change in the natural logarithm of volume over time was estimated for each
animal from a linear regression, and mean slopes were compared using a
t test. For the SKMel28 animal study, p values were adjusted according to
Hochberg (1988). The two-sided Wilcoxon two-sample test was used when
assumptions for the t test were violated (Figure 3A); otherwise, the Student’sCancer Cell 23, 811–825, June 10, 2013 ª2013 Elsevier Inc. 823
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Inhibition of Slow-Cycling Melanoma Cellst test was used. Box plots show the sampleminimum (lower whisker), the lower
quartile (bottom of the box), the median (line inside the box), the upper quartile
(top of the box), and the sample maximum (upper whisker). A p value of less
than 0.05 was considered significant. As software tools, SAS version 9.2 using
Proc GLM and Microsoft Excel were used.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2013.05.003.
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